Jacek Gan
Overview
Explore the profile of Jacek Gan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
962
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu A, Gilman A, Ozkaynak M, Naranjo A, Diccianni M, Gan J, et al.
Clin Cancer Res
. 2021 Jan;
27(8):2179-2189.
PMID: 33504555
Purpose: Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to...
2.
Goldberg J, Navid F, Hank J, Erbe A, Santana V, Gan J, et al.
J Immunother Cancer
. 2020 Mar;
8(1).
PMID: 32169872
Purpose: Patients with cancer receiving tumor-reactive humanized monoclonal antibody (mAb) therapy can develop a human antihuman antibody (HAHA) response against the therapeutic mAb. We evaluated for HAHA in patients with...
3.
Shusterman S, Naranjo A, Van Ryn C, Hank J, Parisi M, Shulkin B, et al.
Clin Cancer Res
. 2019 Jul;
25(20):6044-6051.
PMID: 31358541
Purpose: Combining anti-GD2 (disialoganglioside) mAb with GM-CSF, IL2, and isotretinoin is now FDA-approved for high-risk neuroblastoma minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has...
4.
Albertini M, Yang R, Ranheim E, Hank J, Zuleger C, Weber S, et al.
Cancer Immunol Immunother
. 2018 Aug;
67(10):1647-1658.
PMID: 30073390
Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m/day. Preclinical data in IC-treated tumor-bearing mice...
5.
Wang W, Erbe A, Alderson K, Phillips E, Gallenberger M, Gan J, et al.
Cancer Immunol Immunother
. 2016 Jul;
65(9):1047-59.
PMID: 27392940
Infusion of allogeneic NK cells is a potential immunotherapy for both hematopoietic malignancies and solid tumors. Interactions between killer immunoglobulin-like receptors (KIR) on human NK cells and KIR-ligands on tumor...
6.
Navid F, Sondel P, Barfield R, Shulkin B, Kaufman R, Allay J, et al.
J Clin Oncol
. 2014 Apr;
32(14):1445-52.
PMID: 24711551
Purpose: The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related...
7.
Yang R, Kalogriopoulos N, Rakhmilevich A, Ranheim E, Seo S, Kim K, et al.
Cancer Immunol Immunother
. 2013 May;
62(8):1303-13.
PMID: 23661160
Hu14.18-IL2 is an immunocytokine (IC) consisting of human IL-2 linked to hu14.18 mAb, which recognizes GD2 disialoganglioside. Phase II clinical trials of intravenous-hu14.18-IL2 (IV-IC) in neuroblastoma and melanoma are underway,...
8.
Yang R, Kalogriopoulos N, Rakhmilevich A, Ranheim E, Seo S, Kim K, et al.
J Immunol
. 2012 Jul;
189(5):2656-64.
PMID: 22844125
hu14.18-IL-2 (IC) is an immunocytokine consisting of human IL-2 linked to hu14.18 mAb, which recognizes the GD2 disialoganglioside. Phase 2 clinical trials of i.v. hu14.18-IL-2 (i.v.-IC) in neuroblastoma and melanoma...
9.
Albertini M, Hank J, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, et al.
Cancer Immunol Immunother
. 2012 Jun;
61(12):2261-71.
PMID: 22678096
Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. In this phase II study, 14 patients...
10.
Lange B, Yang R, Gan J, Hank J, Sievers E, Alonzo T, et al.
Pediatr Blood Cancer
. 2011 Jun;
57(3):398-405.
PMID: 21681921
Purpose: To assess associations of soluble IL-2 receptor alpha (sIL-2rα) concentration with outcomes in pediatric acute myeloid leukemia (AML) in a phase 3 trial of IL-2 therapy. Procedures: We randomized...